COST-UTILITY ANALYSIS OF APREMILAST FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN SPAIN

被引：3
|
作者：
Carrascosa, J. M. [1 ]
Vanaclocha, F. [2 ]
Caloto, T. [3 ]
Echave, M. [4 ]
Oyaguez, I [4 ]
Tencer, T. [5 ]
机构：
[1] Germans Trias & Pujol Univ Hosp, Dept Dermatol, Barcelona, Spain
[2] 12 Octubre Univ Hosp, Dept Dermatol, Madrid, Spain
[3] Celgene Corp, Dept Hlth Econ, Madrid, Spain
[4] Pharmacoecon & Outcomes Res Iberia, Madrid, Spain
[5] Celgene Corp, Warren, NJ USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.555
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS31
引用
收藏
页码：A420 / A420
页数：1
相关论文
共 50 条
  • [31] COST-UTILITY EVALUATION COMPARING DISEASE PROGRESSION IN MODERATE VERSUS SEVERE PSORIASIS IN ADULTS IN THE UNITED KINGDOM
    Szewczenko, I
    Jackson, D.
    Thompson, P.
    Betts, A.
    VALUE IN HEALTH, 2020, 23 : S595 - S595
  • [32] Apremilast for the management of moderate to severe plaque psoriasis
    Vangipuram, Ramya
    Alikhan, Ali
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (04) : 349 - 360
  • [33] Economic evaluation of apremilast in the treatment of moderate to severe psoriasis in the United States
    Tencer, Tom
    Clancy, Zoe
    Damera, Vidya
    Zhang, Frank
    Cure, Sandrine
    Feldman, Steven
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB97 - AB97
  • [34] Apremilast and Systemic Retinoid Combination Treatment for Moderate to Severe Palmoplantar Psoriasis
    Czarnowicki, Tali
    Rosendorff, B. Peter
    Lebwohl, Mark G.
    CUTIS, 2020, 106 (01): : E15 - E17
  • [35] A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast
    Chiricozzi, Andrea
    Caposiena, Dante
    Garofalo, Virginia
    Cannizzaro, Maria Vittoria
    Chimenti, Sergio
    Saraceno, Rosita
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2016, 12 (03) : 237 - 249
  • [36] Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
    Papp, Kim
    Cather, Jennifer C.
    Rosoph, Les
    Sofen, Howard
    Langley, Richard G.
    Matheson, Robert T.
    Hu, ChiaChi
    Day, Robert M.
    LANCET, 2012, 380 (9843): : 738 - 746
  • [37] Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis
    Bianchi, Luca
    Del Duca, Ester
    Romanelli, Marco
    Saraceno, Rosita
    Chimenti, Sergio
    Chiricozzi, Andrea
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (09) : 1121 - 1128
  • [38] Cost-effectiveness of apremilast in moderate-to-severe chronic plaque psoriasis: a model analysis in the UK
    Mughal, F.
    Barker, J.
    Cawston, H.
    Damera, V.
    Bewley, A.
    Morris, J.
    Shaw, T.
    Tencer, T.
    Zhang, F.
    BRITISH JOURNAL OF DERMATOLOGY, 2016, 175 : 74 - 74
  • [39] COST-UTILITY OF DENOSUMAB FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS IN SPAIN
    Darba, J.
    Kaskens, L.
    Sorio, F.
    VALUE IN HEALTH, 2011, 14 (07) : A311 - A311
  • [40] Cost-Utility Analysis of Biologic Treatments for Moderate-to-Severe Crohn's Disease
    Tang, Derek H.
    Armstrong, Edward P.
    Lee, Jeannie K.
    PHARMACOTHERAPY, 2012, 32 (06): : 515 - 526
12345